Lymphocyte

Type: Product
Name: Lymphocyte
First reported 15 hours ago - Updated 2 hours ago - 7 reports

FDA Approves New Cancer Medication

Zydelig approved to treat certain blood cancersJuly 23, 2014 / Author: / Reviewed by: Joseph V. Madia, MDRate This ArticleAverage Rating3.85Your Rating(dailyRx News) The US Food and Drug Administration (FDA) approved Zydelig (idelalisib) today to treat ... [Published Daily Rx - 2 hours ago]
First reported 12 hours ago - Updated 3 hours ago - 1 reports

Will controversial hepatitis C drug continue its blockbuster sales?

Gilead Sciences’ $1,000-a-day hepatitis C pill is facing a firestorm of criticism from insurers and lawmakers, but none of those obstacles are likely to stop the Foster City company from reporting blockbuster revenues during the second quarter today.In ... [Published San Francisco Chronicle - 12 hours ago]
First reported 10 hours ago - Updated 4 hours ago - 1 reports

Gilead earnings: $2.36 per share adjusted, vs. expected EPS of $1.79

scientist for Gilead Sciences, works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster City, California, U.S., on Wednesday, Feb. 8, 2012.Analysts had expected the company to report earnings of $1.79 a share ... [Published CNBC - 10 hours ago]
First reported 13 hours ago - Updated 6 hours ago - 2 reports

FDA approves idelalisib for three leukemia and lymphoma indications

The oral kinase inhibitor idelalisib has been approved for treating patients with relapsed chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma, with a boxed warning... ... [Published Cardiology News - 6 hours ago]
First reported 18 hours ago - Updated 8 hours ago - 1 reports

Storming Tecfidera sales drive 46% profit rise at Biogen

Biogen Idec has posted second-quarter results which show that sales of its oral multiple sclerosis drug Tecfidera have comfortably passed analyst forecasts, pushing net profits up 46%.Earnings came in at $714.5 million, while revenues increased 40% to ... [Published Pharma Times - 18 hours ago]
First reported 14 hours ago - Updated 8 hours ago - 2 reports

Zydelig Approved for Three Types of Blood Cancer

(HealthDay News) -- Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic ... [Published Health Day - 12 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma ... [Published PR Newswire: Policy & Public Interest - 9 hours ago]
First reported Jul 22 2014 - Updated 14 hours ago - 3 reports

Medical News Today: 'Pathogenic connection' between cancer and autoimmune disorders

"Researchers from George Washington University in Washington, DC, and the Roswell Park Cancer Institute in Buffalo, NY, have found that tumors and the cells implicated in autoimmune diseases both express the same inhibitors of cell destruction.Survivin, ... [Published Bayou Buzz - 21 hours ago]
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Lion Biotechnologies Leases New Research Laboratory

(GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. ( OTCQB:LBIO ), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has entered into a five-year lease agreement ... [Published Crawford Financial Planning - 18 hours ago]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

VIRAL VULNERABILITY

TAPAN KUMAR MAITRAELABORATES ON CANCER-CAUSING AGENTSAlthough the cancer causing properties of chemicals and radiation were recognised by the early 1900s, the possibility that infectious agents might also cause cancer was not widely appreciated because ... [Published The Statesman - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Breakthrough in leukemia

Mr. Smith is a 75-year-old gentleman who was diagnosed with CLL, or chronic lymphocytic leukemia, almost 10 years ago.CLL causes a slow increase in a certain type of white blood cells called B lymphocytes or B cells. Cancer cells spread through the blood ... [Published Citrus County Chronicle - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Research and Markets: 2014 Global Non-Hodgkin Lymphoma Therapeutics Market Report Featuring Bristol Myers Squibb, Celgen, Eli Lilly and Co, F. Hoffman La-Roche & GSK

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d9bzj5/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) ... [Published Business Wire Health News - Jul 22 2014]

Quotes

"Talk to your pharmacist about emerging treatments for your condition."
"The fundamental concern is Sovaldi and other speciality drugs are going to put an unsustainable burden on the health insurance system" said John Rother, CEO of the National Coalition on Health Care, which lobbies for health-system reform...
"The invention further provides for a pharmaceutical composition comprising an IRO compound according to the invention and a pharmaceutically acceptable carrier."

More Content

All (668) | News (536) | Reports (1) | Blogs (114) | Audio/Video (0) | Fact Sheets (0) | Press Releases (10)
sort by: Date | Relevance
FDA Approves New Cancer Medication [Published Daily Rx - 2 hours ago]
Gilead Sciences' (GILD) CEO John Martin on Q2 2... [Published Yahoo! Finance - 3 hours ago]
Gilead pill reaches $3.48B in quarterly sales [Published San Francisco Chronicle - 3 hours ago]
IDERA PHARMACEUTICALS : Patent Application Titl... [Published 4 Traders - 4 hours ago]
Patent Issued for Method of Using Beta-Hydroxy-... [Published 4 Traders - 4 hours ago]
Patent Issued for Composition for Targeting Den... [Published 4 Traders - 5 hours ago]
Gilead's Sovaldi tops estimates with Q2 sales o... [Published FirstWord Pharma - 6 hours ago]
FDA Confirms Approval of Gilead's Zydelig; FDA ... [Published BioMedReports - 6 hours ago]
FDA Approves Indications for Zydelig for Three ... [Published Oncology Times - 6 hours ago]
FDA approves idelalisib for three leukemia and ... [Published Cardiology News - 6 hours ago]
AASTROM BIOSCIENCES : Patent Application Titled... [Published 4 Traders - 7 hours ago]
Patent Issued for Extracellular Matrix Cancer V... [Published HispanicBusiness.com - 7 hours ago]
Biogen, Gilead Earnings Crush Q2 Estimates [Published Yahoo! Finance - 8 hours ago]
Patent Issued for Substances, Compositions and ... [Published 4 Traders - 9 hours ago]
The Leukemia & Lymphoma Society Applauds FDA's ... [Published CEOWorld Magazine - 9 hours ago]
The Leukemia & Lymphoma Society Applauds FDA's ... [Published PR Newswire: Policy & Public Interest - 9 hours ago]
Gilead earnings: $2.36 per share adjusted, vs. ... [Published CNBC - 10 hours ago]
Rosacea and Chronic Rhinosinusitis: A Case-Cont... [Published Sexual Development - 11 hours ago]
UPDATED: Gilead picks up blockbuster FDA blood ... [Published FierceBiotech - 12 hours ago]
Zydelig Approved for Three Types of Blood Cancer [Published Health Day - 12 hours ago]
UPDATE 1-U.S. FDA approves Gilead blood cancer ... [Published CNBC - 12 hours ago]
Will controversial hepatitis C drug continue it... [Published San Francisco Chronicle - 12 hours ago]
Gilead Edges Into Cancer Field With FDA OK of C... [Published Xconomy - 12 hours ago]
Idelalisib (Zydelig) Approved for CLL and Lymphoma [Published Diabetes Care - 13 hours ago]
Zydelig approved by FDA to treat three types of... [Published Drug Store News - 13 hours ago]
Gilead picks up blockbuster FDA blood cancer ap... [Published FierceBiotech - 13 hours ago]
FDA clears Gilead's Zydelig for three types of ... [Published FirstWord Pharma - 13 hours ago]
IN MEMORY OF Doretta Lucy Swenhaugen [Published Murray County News - 14 hours ago]
U.S. FDA approves Gilead's blood cancer drug Zy... [Published CNBC - 14 hours ago]
U.S. Food and Drug Administration Approves Gile... [Published Nasdaq - 14 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Leukemia & Lymphoma Society Applauds FDA's ... [Published PR Newswire: Policy & Public Interest - 9 hours ago]
WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma ...
U.S. Food and Drug Administration Approves Gile... [Published Business Wire Health News - 15 hours ago]
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Zydelig® (idelalisib) 150 mg tablets for the treatment of three B-cell blood cancers. Zydelig is indicated ...
Frontrunning: July 22 [Published Zero Hedge - Jul 22 2014]
EU Works to Punish Russia as MH17 Bodies Leave Rebel Area ( BBG ) Bodies From Malaysia Airlines Flight Begin Long Trip to Netherlands ( WSJ ) Israel pounds Gaza as Kerry arrives ( Reuters ) U.S. judge dismisses Republican lawsuit over Obamacare subsidy ...
Research and Markets: 2014 Global Non-Hodgkin L... [Published Business Wire Health News - Jul 22 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d9bzj5/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) ...
a gene that links stem cells, aging and cancer [Published 3quarksdaily - Jul 18 2014]
From Medical Xpress: An organism is healthy thanks to a good maintenance system: the normal functioning of organs and environmental exposure cause damage to tissues, which need to be continuously repaired. This process is not yet well understood, ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Lion Biotechnologies Leases New Research Labora... [Published GlobeNewswire: Acquisitions News - 18 hours ago]
GSK and Genmab announce top-line results from a... [Published GlobeNewswire: Advertising News - Jun 27 2014]
Lion Biotechnologies Appoints Dr. Laszlo Radvan... [Published GlobeNewswire: Advertising News - Jun 23 2014]
MacroGenics Initiates Phase 1 Study of MGD006 f... [Published GlobeNewswire: Acquisitions News - Jun 19 2014]
Lion Biotechnologies to Present at the Jefferie... [Published GlobeNewswire: Acquisitions News - May 27 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.